Response to Michael Wonder's comments on the article 'Assessment of the therapeutic value of new medicines marketed in Australia'.
作者信息
Vitry Agnes I
机构信息
Quality Use of Medicines and Pharmacy Research Centre, Sansom Institute for Health Sciences, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide Australia.
出版信息
J Pharm Policy Pract. 2013 Oct 10;6:8. doi: 10.1186/2052-3211-6-8. eCollection 2013.
Abstract
摘要
相似文献
1
Response to Michael Wonder's comments on the article 'Assessment of the therapeutic value of new medicines marketed in Australia'.对迈克尔·旺德就《澳大利亚上市新药治疗价值评估》一文发表的评论的回应。
J Pharm Policy Pract. 2013 Oct 10;6:8. doi: 10.1186/2052-3211-6-8. eCollection 2013.
2
Assessment of the therapeutic value of new medicines marketed in Australia.对在澳大利亚上市的新药的治疗价值评估。
J Pharm Policy Pract. 2013 Sep 10;6:7. doi: 10.1186/2052-3211-6-7. eCollection 2013.
3
Registration and Reimbursement of New Cancer Medicines in Australia-Response to Letter to the Editor by Michael Wonder.澳大利亚新型癌症药物的注册与报销——对迈克尔·旺德致编辑信的回应
Value Health Reg Issues. 2016 May;9:65-66. doi: 10.1016/j.vhri.2015.10.008. Epub 2016 Feb 2.
4
Correction to: 'New theropod (Tetanurae: Avetheropoda) material from the 'mid'-Cretaceous Griman Greek Formation at Lightning Ridge, New South Wales, Australia'.对《来自澳大利亚新南威尔士州闪电岭“中”白垩世格里曼希腊组的新兽脚亚目（坚尾龙类：鸟兽脚类）材料》的修正
R Soc Open Sci. 2019 Feb 20;6(2):190230. doi: 10.1098/rsos.190230. eCollection 2019 Feb.
5
Response to Kottek and Kilpatrick, 'Estimating Occupational Exposure to Asbestos in Australia'.对科泰克和基尔帕特里克所著《澳大利亚石棉职业暴露评估》的回应
Ann Occup Hyg. 2016 May;60(4):533-5. doi: 10.1093/annhyg/mew010. Epub 2016 Mar 10.
6
The role of the Therapeutic Goods Administration and the Medicine and Medical Devices Safety Authority in evaluating complementary and alternative medicines in Australia and New Zealand.澳大利亚治疗用品管理局以及新西兰药品与医疗器械安全管理局在评估补充和替代药物方面所发挥的作用。
Toxicology. 2006 Apr 3;221(1):88-94. doi: 10.1016/j.tox.2005.12.023. Epub 2006 Feb 14.
7
A response to Pienaar et al (2018) 'Problematizing LGBTIQ drug use, governing sexuality and gender: A critical analysis of LGBTIQ health policy in Australia'.对皮纳尔等人（2018年）《质疑LGBTIQ群体的药物使用、性取向与性别治理：对澳大利亚LGBTIQ健康政策的批判性分析》的回应
Int J Drug Policy. 2018 May;55:195-196. doi: 10.1016/j.drugpo.2018.04.016.
8
'Response to Midwifery students' experiences of an innovative clinical placement model embedded within midwifery continuity of care in Australia'.对澳大利亚助产士连续性护理中创新型临床实习模式下助产专业学生经历的回应
Midwifery. 2015 Oct;31(10):e97-8. doi: 10.1016/j.midw.2015.08.005. Epub 2015 Aug 15.
9
Response to: 'Sentinel lymph node biopsy for in situ melanoma is unlikely in Australia' by Morton and Thompson.对莫顿和汤普森所著的《澳大利亚原位黑色素瘤前哨淋巴结活检不太可能实现》一文的回应。
BMJ Qual Saf. 2019 Mar;28(3):255-256. doi: 10.1136/bmjqs-2018-009213. Epub 2019 Jan 3.
10
Thoughts on 'Redefining residential rehabilitation in Australia'.关于《重新定义澳大利亚的住院康复》的思考
Australas Psychiatry. 2017 Aug;25(4):414. doi: 10.1177/1039856216689534.
本文引用的文献
1
An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011.一种改进的药物创新衡量方法发现，1987-2011 年，首创类药物的研发速度稳定。
Health Aff (Millwood). 2013 Aug;32(8):1433-9. doi: 10.1377/hlthaff.2012.0541.
2
Communicating uncertainties about prescription drugs to the public: a national randomized trial.向公众传达处方药的不确定性：一项全国性随机试验。
Arch Intern Med. 2011 Sep 12;171(16):1463-8. doi: 10.1001/archinternmed.2011.396.
3
Building comparative efficacy and tolerability into the FDA approval process.将比较疗效和耐受性纳入美国食品药品监督管理局的批准流程。
JAMA. 2010 Mar 10;303(10):979-80. doi: 10.1001/jama.2010.257.
4
Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers.药物的相对疗效：监管机构与第三方支付者之间的一个新兴问题。
Nat Rev Drug Discov. 2010 Apr;9(4):277-91. doi: 10.1038/nrd3079. Epub 2010 Feb 26.
5
Medicines regulation and health technology assessment.药品监管与卫生技术评估。
Clin Pharmacol Ther. 2010 Feb;87(2):152-4. doi: 10.1038/clpt.2009.261.
6
Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval.渐进式进步还是重大变革？提高药物审批效力标准的必要性。
J Clin Oncol. 2009 Dec 10;27(35):5868-73. doi: 10.1200/JCO.2009.22.4162. Epub 2009 Oct 13.
7
How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question.生命价值几何：西妥昔单抗、非小细胞肺癌与那4400亿美元的问题
J Natl Cancer Inst. 2009 Aug 5;101(15):1044-8. doi: 10.1093/jnci/djp177. Epub 2009 Jun 29.
Zotero 插件